Formulation and evaluation of voriconazole nanocapsules

Subba Rao G, Sowmy Adapa
{"title":"Formulation and evaluation of voriconazole nanocapsules","authors":"Subba Rao G, Sowmy Adapa","doi":"10.26452/ijebr.v3i1.565","DOIUrl":null,"url":null,"abstract":"The current study's goal was to create as well as assess voriconazole nanocapsules using the diffusion of emulsion solvent technology. Voriconazole was made using the emulsion solvent diffusion method and is loaded with ethyl cellulose and HPMC Nanocapsules. The FTIR data showed that there was no drug-polymer interaction and that voriconazole nanocapsules filled with ethyl cellulose were stable. The absence of incompatibility in the formulation was investigated using compatability investigations such as FTIR and DSC. SEM is used to determine the morphological particle size of the voriconazole nanocapsules. F1 through F8 are the complete formulation codes for which the nanocapsules were tested. A percentage yield of 83.32% to 88.61% was discovered. There was 65.8 to 98.5% drug content. The nanocapsules' particle size ranged from 78 µm to 33 µm, while their drug entrapment effectiveness ranged from 54.4% to 91.4% and their drug loading capacity from 56.8% to 97.7%. The study period for swellability was 0.8 to 1.5 seconds. The optimal formulation, F8, showed an in vitro dissolving rate of 61.89%. Numerous mathematical models, including zero order, first order, Higuchi matrix, and Korsmeyer Peppas model, were fitted to the available data on drug dissolution in vitro. The R2 value and m value of the Voriconazole Nanocapsules model were 0.937, 0.399, 0.899, 0.785, and 2.560, respectively. Up to 45 mints of medication were released from the nanocapsules. The HPMC and ethyl cellulose-loaded Voriconazole nanocapsules were made under ideal circumstances and have good release properties.","PeriodicalId":398836,"journal":{"name":"International Journal of Experimental and Biomedical Research","volume":"35 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Experimental and Biomedical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26452/ijebr.v3i1.565","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The current study's goal was to create as well as assess voriconazole nanocapsules using the diffusion of emulsion solvent technology. Voriconazole was made using the emulsion solvent diffusion method and is loaded with ethyl cellulose and HPMC Nanocapsules. The FTIR data showed that there was no drug-polymer interaction and that voriconazole nanocapsules filled with ethyl cellulose were stable. The absence of incompatibility in the formulation was investigated using compatability investigations such as FTIR and DSC. SEM is used to determine the morphological particle size of the voriconazole nanocapsules. F1 through F8 are the complete formulation codes for which the nanocapsules were tested. A percentage yield of 83.32% to 88.61% was discovered. There was 65.8 to 98.5% drug content. The nanocapsules' particle size ranged from 78 µm to 33 µm, while their drug entrapment effectiveness ranged from 54.4% to 91.4% and their drug loading capacity from 56.8% to 97.7%. The study period for swellability was 0.8 to 1.5 seconds. The optimal formulation, F8, showed an in vitro dissolving rate of 61.89%. Numerous mathematical models, including zero order, first order, Higuchi matrix, and Korsmeyer Peppas model, were fitted to the available data on drug dissolution in vitro. The R2 value and m value of the Voriconazole Nanocapsules model were 0.937, 0.399, 0.899, 0.785, and 2.560, respectively. Up to 45 mints of medication were released from the nanocapsules. The HPMC and ethyl cellulose-loaded Voriconazole nanocapsules were made under ideal circumstances and have good release properties.
伏立康唑纳米胶囊的制备与评估
本研究的目标是利用乳液溶剂扩散技术制造并评估伏立康唑纳米胶囊。伏立康唑采用乳液溶剂扩散法制成,并装入乙基纤维素和 HPMC 纳米胶囊。傅立叶变换红外光谱数据表明,药物与聚合物之间不存在相互作用,乙基纤维素填充的伏立康唑纳米胶囊是稳定的。利用傅立叶变换红外光谱和 DSC 等相容性研究法调查了制剂中是否存在不相容性。扫描电镜用于确定伏立康唑纳米胶囊的形态粒度。F1 至 F8 是测试纳米胶囊的完整配方代码。发现产量百分比为 83.32% 至 88.61%。药物含量为 65.8%至 98.5%。纳米胶囊的粒径从 78 微米到 33 微米不等,其药物包封效果从 54.4% 到 91.4% 不等,药物负载能力从 56.8% 到 97.7% 不等。膨胀性的研究周期为 0.8 至 1.5 秒。最佳配方 F8 的体外溶解率为 61.89%。根据现有的药物体外溶解数据拟合了许多数学模型,包括零阶、一阶、樋口矩阵和 Korsmeyer Peppas 模型。伏立康唑纳米胶囊模型的 R2 值和 m 值分别为 0.937、0.399、0.899、0.785 和 2.560。从纳米胶囊中释放药物的时间长达 45 分钟。HPMC和乙基纤维素负载的伏立康唑纳米胶囊是在理想的条件下制成的,具有良好的释放性能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信